Organon & Co reports results for the quarter ended March 31 - Earnings Summary

• Organon & Co OGN reported quarterly adjusted earnings of $1.02​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of $1.22. The mean expectation of six analysts for the quarter was for earnings of 90 cents per share. Wall Street expected results to range from 86 cents to 94 cents per share.

• Revenue fell 6.7% to $1.51 billion from a year ago; analysts expected $1.51 billion.

• The company reported quarterly net income of $87 million.

• Organon & Co shares had fallen by 13.2% this quarter and lost 13.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 17.5% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and 3 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "hold"

• Wall Street's median 12-month price target for Organon & Co is $15.00

This summary was machine generated from LSEG data May 1 at 01:33 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)